Emerging Markets Earnings Roundup: Roche (Part 2)
This article was originally published in PharmAsia News
Executive Summary
Roche feels the heat still from Tarceva competition in China, but Japan regains luster as sales tax hit dims and diagnostics benefit as governments in emerging markets ramp up health care spending.
You may also be interested in...
Roche PD-L1 Bladder Cancer Filing Set For 2016; Investors Hope For Earlier
With limited treatment options available for bladder cancer, being first to market with a paradigm-changing PD-1/PD-L1 inhibitor in the indication could be a big commercial opportunity.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia 2014: Distribution, Manufacturing To The Fore
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.